12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Fri, 20 Feb 2026 06:28:43 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6IlpPblBqaGhTM0VBcEhZamJ2dXpQb2c9PSIsInZhbHVlIjoiM1JcL3BzZFwvZEVodk5QdnlBXC93bTBKV21mQVRIN1lrMmlERzJYVkRKS09wcEFWcmdXbkpmVm1hY2pXTEtrazMwWDRwTTJocEUrU0hWUHFFYloxSVJhQVE9PSIsIm1hYyI6IjZhOWJlNzViMGJkNzFjMDdhMzMyODEwNmFiYTBhYzdhMGRkYzVjZWQyYTI0YWM5MDdiOTUzYTEzMTE4NTZiMmIifQ%3D%3D; expires=Mon, 19-Feb-2029 06:28:43 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Sat, 21 Feb 2026 06:28:43 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=ibwAX%2F3rMMoLDhQVzPGukcWoZcoSbd8sDAx%2FcS0xdPpKcGLIkrGWgvkcNsbBhhXnTLW0fWX3Rr5p44DfOBV%2Bq5C9erKvgi%2FN%2B%2BWaM539Vg%3D%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=12,cfOrigin;dur=793 [24] => CF-RAY: 9d0bf2073cf80ff3-LAX [25] => alt-svc: h3=":443"; ma=86400 ) 789

日本NHK报道，研究人员已完成人工衍生干细胞培养的眼角膜移植，这是世界临床试验首例。

由大阪大学教授西田浩次带领的一群研究人员周四向外发表成果。研究人员表示，他们上月25日在一名40多岁严重眼角膜疾病女患者的左眼进行移植手术。

他们说，当时使用人类诱导性多能干细胞(iPS)培养片状角膜组织。医生表示，患者尚未出现排斥反应，她的视力恢复，所以日常生活不再有困扰，已在23日顺利出院。

该团队打算今年年底在第二名病患进行相同的移植手术，并于明年再进行两次。该研究是使用人类诱导性多能干细胞的一系列临床试验中最新研究，包括将视网膜细胞移植到不同眼睛疾病的病患眼中。

西田教授表示，原本几乎丧失视力的的女病患已恢复阅读信件的能力。但许多关于眼角膜疾病的疗法依然未知，他的团队希望仔细检视安全性和效果。

---

// // // //